Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STACT-TREX1
- Development stage
- Preclinical
- Lead developer
- Actym Therapeutics
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, RNA Therapeutics → Nucleic Acid Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
STACT-TREX1 is a first-in-class, systemically administered microbial-based immunotherapy developed by Actym Therapeutics using its proprietary STACT (Salmonella typhimurium (Attenuated) + Cancer Therapy) platform. The therapy consists of a genetically engineered, attenuated strain of Salmonella typhimurium designed to selectively accumulate in the tumor microenvironment. Once localized, it delivers inhibitory microRNA (RNAi) to the myeloid compartment to silence TREX1, a 3′ exonuclease that acts as an immune checkpoint by degrading cytosolic DNA and preventing the activation of the cGAS-STING pathway. By inhibiting TREX1, STACT-TREX1 promotes STING-mediated immune activation, leading to potent anti-tumor activity. Preclinical studies have demonstrated its efficacy as a monotherapy, resulting in significant tumor growth inhibition and complete regressions in models of colon carcinoma and melanoma.
02
Targets
TREX1 (Three-prime repair exonuclease 1)STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on STACT-TREX1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STACT-TREX1.